Qualitime Plans to Reach a Turnover of €11 Million in 2026

Qualitime, a startup dedicated to organizing visits between laboratories and healthcare professionals through its mobile application to optimize communication between both parties expects to invoice eleven million euros in 2026, as confirmed by its founder Antonio López.

The director has assured that the calculations have been based on only fifteen of the more than 300 laboratories in Spain, seeking the greatest possible reliability for their predictions.

Currently, the mobile solution developed by Qualitime is only available in its free version, but López hopes to start monetizing from March 2024, when the version becomes paid for visitors to these laboratories. In this direction, López expects to invoice €700,000 in 2024. 

Therefore, his forecasts involve multiplying his turnover by fifteen in two years. His time at Lanzadera, which he joined in this September’s call, is essential to be able to develop his jump into the market, according to the manager.

López has stated that in March, in parallel with the monthly recurring revenue (MRR), he will seek to implement a series of technological adjustments that improve the profitability of the application and allow the subscription model to be included. This will open the doors of investment, and ” in the coming months we hope to raise a financing round of about €300,000, although we still have to adjust this figure.”

Read more about Qualitime and find other important financial news of the day with the Born2Invest mobile app.

Qualitime application has 1,800 visitors from the main laboratories in the country and 400 registered doctors

Although the first version of the application came out in 2020, the pandemic disrupted the company’s plans. López has assured that this situation, after prohibiting in-person visits to hospitals and health centers, “motivated us to develop a virtual visit option, so now doctors can attend in person or digitally,” as the manager explained.

At the moment, the application has 1,800 registered visitors from the main laboratories in the country and about 400 health workers from the autonomous centers with the most weight within the national sector. Mainly, although healthcare professionals cover a wide range of specialties, the main registered fields are dermatology, internal medicine, and allergology.

The team plans to make the international leap in 2026, to establish itself in the large European markets (Germany, France, England, and Italy) a year later. In 2028, López contemplated landing in the United States, although he recognized that the Latin American market is “much more feasible, since by sharing a language we should not make major changes in terms of operating systems.”

However, López has stated that the main current motivation is to expand the national medical community. The service offers the possibility of sending information pills by pharmaceutical laboratories to facilitate direct communication with health professionals. With this, the manager has predicted optimizing costs and resources, since visitors “usually lose about four hours a day as a result of long waiting times.”

__

(Featured image by terimakasih0 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.